DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - US26622P1075 - Common Stock
66.4 USD
-1.34 (-1.98%)
66.4 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to DOCS. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is valued quite expensively, but it does show have an excellent growth rating. With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.65%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Return On Equity of 20.62% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.07%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.68%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(17.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROIC | 17.07% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
Looking at the Profit Margin, with a value of 39.13%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS's Operating Margin of 40.34% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
DOCS has a Gross Margin of 90.20%. This is amongst the best in the industry. DOCS outperforms 97.14% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DOCS is still creating some value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
The number of shares outstanding for DOCS has been increased compared to 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 43.22. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
DOCS has a Altman-Z score of 43.22. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 43.22 |
ROIC/WACC1.71
WACC9.99%
2.3 Liquidity
A Current Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a better Current ratio (6.97) than 94.29% of its industry peers.
DOCS has a Quick Ratio of 6.97. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DOCS (6.97) is better than 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 43.27% over the past year.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 19.98% in the last year.
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
Revenue 1Y (TTM)19.98%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
3.2 Future
The Earnings Per Share is expected to grow by 13.47% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.87% on average over the next years. This is quite good.
EPS Next Y9.92%
EPS Next 2Y9.06%
EPS Next 3Y10.09%
EPS Next 5Y13.47%
Revenue Next Year12.02%
Revenue Next 2Y11.46%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 44.56, DOCS can be considered very expensive at the moment.
DOCS's Price/Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 71.43% of the companies in the same industry.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.03.
The Price/Forward Earnings ratio is 39.60, which means the current valuation is very expensive for DOCS.
DOCS's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.63. DOCS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.56 | ||
| Fwd PE | 39.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS is on the same level as its industry peers.
DOCS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.62 | ||
| EV/EBITDA | 44.92 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.49
PEG (5Y)0.56
EPS Next 2Y9.06%
EPS Next 3Y10.09%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
66.4
-1.34 (-1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners96.64%
Inst Owner Change-2.61%
Ins Owners1.94%
Ins Owner Change0.03%
Market Cap12.44B
Analysts76.92
Price Target69.7 (4.97%)
Short Float %3.05%
Short Ratio2.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.65%
Min EPS beat(2)30.62%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)26.68%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.85%
EPS beat(12)12
Avg EPS beat(12)22.9%
EPS beat(16)16
Avg EPS beat(16)34.8%
Revenue beat(2)2
Avg Revenue beat(2)4.77%
Min Revenue beat(2)1.38%
Max Revenue beat(2)8.16%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)6
Avg Revenue beat(8)2.85%
Revenue beat(12)8
Avg Revenue beat(12)1.88%
Revenue beat(16)12
Avg Revenue beat(16)3.35%
PT rev (1m)7.99%
PT rev (3m)-5.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.75%
EPS NY rev (1m)7.26%
EPS NY rev (3m)16.04%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-0.37%
Revenue NY rev (1m)1.21%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.56 | ||
| Fwd PE | 39.6 | ||
| P/S | 21.8 | ||
| P/FCF | 46.62 | ||
| P/OCF | 45.51 | ||
| P/B | 11.49 | ||
| P/tB | 12.54 | ||
| EV/EBITDA | 44.92 |
EPS(TTM)1.49
EY2.24%
EPS(NY)1.68
Fwd EY2.53%
FCF(TTM)1.42
FCFY2.14%
OCF(TTM)1.46
OCFY2.2%
SpS3.05
BVpS5.78
TBVpS5.29
PEG (NY)4.49
PEG (5Y)0.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROCE | 20.77% | ||
| ROIC | 17.07% | ||
| ROICexc | 98.29% | ||
| ROICexgc | 186.54% | ||
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% | ||
| FCFM | 46.76% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.5% | ||
| Profit Quality | 119.52% | ||
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 | ||
| Altman-Z | 43.22 |
F-Score9
WACC9.99%
ROIC/WACC1.71
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
EPS Next Y9.92%
EPS Next 2Y9.06%
EPS Next 3Y10.09%
EPS Next 5Y13.47%
Revenue 1Y (TTM)19.98%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
Revenue Next Year12.02%
Revenue Next 2Y11.46%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y33.93%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.83%
EBIT Next 3Y13.34%
EBIT Next 5Y12.98%
FCF growth 1Y49.61%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y48.44%
OCF growth 3Y29.24%
OCF growth 5Y59.83%